Illumina, Inc. (ILMN)
| Market Cap | 40.46B +177.0% |
| Revenue (ttm) | 4.49B +4.9% |
| Net Income | 824.00M -34.4% |
| EPS | 5.37 -32.1% |
| Shares Out | 151.00M |
| PE Ratio | 49.89 |
| Forward PE | 47.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,989,234 |
| Open | 267.24 |
| Previous Close | 271.76 |
| Day's Range | 257.14 - 275.49 |
| 52-Week Range | 90.10 - 309.35 |
| Beta | 1.42 |
| Analysts | Buy |
| Price Target | 241.05 (-10.03%) |
| Earnings Date | Oct 29, 2026 |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price target is $241.05, which is a decrease of -10.03% from the latest price.
News
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight Inc...
Illumina sets up commercial paper program for up to $1.0B
On October 8, Illumina (ILMN) “entered into definitive documentation to establish an unsecured commercial paper program pursuant to which the Company may issue short-term, unsecured commercial paper n...
Illumina price target raised to $270 from $210 at TD Cowen
TD Cowen raised the firm’s price target on Illumina (ILMN) to $270 from $210 and keeps a Hold rating on the shares. The firm adjusted targets in the life science…
Illumina price target raised to $168 from $140 at BofA
BofA raised the firm’s price target on Illumina (ILMN) to $168 from $140 and keeps an Underperform rating on the shares. The life science tools sector has further re-rated since…
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026....
Illumina releases SpliceAI2 to help advance rare disease research
In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identi...
Illumina price target raised to $200 from $160 at Barclays
Barclays raised the firm’s price target on Illumina (ILMN) to $200 from $160 and keeps an Underweight rating on the shares. The firm adjusted targets in the life science and…
Illumina price target raised to $310 from $230 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Illumina (ILMN) to $310 from $230 and keeps an Outperform rating on the shares. The firm notes that its…
Illumina price target raised to $305 from $226 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Illumina (ILMN) to $305 from $226 and keeps a Buy rating on the shares. The firm adjusted its models and…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Illumina price target raised to $300 from $220 at Leerink
Leerink raised the firm’s price target on Illumina (ILMN) to $300 from $220 and keeps an Outperform rating on the shares. The firm cites comparable sales and incremental growth from…
Illumina price target raised to $305 from $225 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Illumina (ILMN) to $305 from $225 and keeps an Overweight rating on the shares. Pharma and biotech spend roughly…
Illumina assumed with a Buy at UBS
UBS assumed coverage of Illumina (ILMN) with a Buy rating and $260 price target Illumina stands out as a compelling revenue reacceleration and margin-expansion opportunity, with high single digit grow...
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of tradi...
Bloom Energy and These 2 Stocks Are Joining the S&P 500
The S&P 500 is getting three new members this month, with Bloom Energy, Everpure, and Illumina joining the benchmark as part of its latest quarterly reshuffle.
Bloom Energy, Everpure, Illumina to be added to S&P 500 at open on 9/21
Dow Jones Indices is making the following changes to the S&P 500 index effective prior to the open of trading on Monday, September 21, to coincide with the quarterly rebalance.
Illumina price target raised to $235 from $180 at Argus
Argus raised the firm’s price target on Illumina (ILMN) to $235 from $180 and keeps a Buy rating on the shares. Illumina is currently working on several new products that…
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Illumina management to meet with Piper Sandler
Meeting to be held on August 27 hosted by Piper Sandler.
Illumina management to meet virtually with Piper Sandler
Virtual Meeting to be held to be held on August 25-26 hosted by Piper Sandler.
Illumina downgraded to Hold from Buy at Freedom Broker
Freedom Broker downgraded Illumina (ILMN) to Hold from Buy with a price target of $185, up from $155. The firm says the company’s “strong quarter reinforces Illumina’s accelerating fundamental growth…
Illumina price target raised to $225 from $200 at Piper Sandler
Piper Sandler raised the firm’s price target on Illumina (ILMN) to $225 from $200 and keeps an Overweight rating on the shares following quarterly results. The firm cites another strong…
Illumina price target raised to $205 from $190 at Canaccord
Canaccord raised the firm’s price target on Illumina (ILMN) to $205 from $190 and keeps a Hold rating on the shares. The firm said the company’s Q2 performance was driven…
Illumina Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue and EPS growth, driven by strong clinical demand, expanding NovaSeq X placements, and innovation in multi-omics and AI-enabled offerings. Full-year guidance was raised for revenue and EPS, with clinical markets and new products expected to drive future growth.